The role of IL‐23 and the IL‐23/TH17 immune axis in the pathogenesis and treatment of psoriasis
Top Cited Papers
Open Access
- 27 June 2017
- journal article
- review article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (10), 1616-1626
- https://doi.org/10.1111/jdv.14433
Abstract
Psoriasis is a chronic, immune‐mediated disease affecting more than 100 million people worldwide and up to 2.2% of the UK population. The aetiology of psoriasis is thought to originate from an interplay of genetic, environmental, infectious and lifestyle factors. The manner in which genetic and environmental factors interact to contribute to the molecular disease mechanisms has remained elusive. However, the interleukin 23 (IL‐23)/T‐helper 17 (TH17) immune axis has been identified as a major immune pathway in psoriasis disease pathogenesis. Central to this pathway is the cytokine IL‐23, a heterodimer composed of a p40 subunit also found in IL‐12 and a p19 subunit exclusive to IL‐23. IL‐23 is important for maintaining TH17 responses, and levels of IL‐23 are elevated in psoriatic skin compared with non‐lesional skin. A number of agents that specifically inhibit IL‐23p19 are currently in development for the treatment of moderate‐to‐severe plaque psoriasis, with recent clinical trials demonstrating efficacy with a good safety and tolerability profile. These data support the role of this cytokine in the pathogenesis of psoriasis. A better understanding of the IL‐23/TH17 immune axis is vital and will promote the development of additional targets for psoriasis and other inflammatory diseases that share similar genetic aetiology and pathogenetic pathways.Keywords
Funding Information
- SUN Pharmaceutical Industries Inc
This publication has 126 references indexed in Scilit:
- Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility LociAmerican Journal of Human Genetics, 2012
- Psoriasis and Other Complex Trait Dermatoses: From Loci to Functional PathwaysJournal of Investigative Dermatology, 2012
- A Subpopulation of CD163-Positive Macrophages Is Classically Activated in PsoriasisJournal of Investigative Dermatology, 2010
- A protective function for interleukin 17A in T cell–mediated intestinal inflammationNature Immunology, 2009
- Investigation of association of the IL12B and IL23R genes with psoriatic arthritisArthritis & Rheumatism, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- Incidence and Risk Factors for Psoriasis in the General PopulationArchives of Dermatology, 2007
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature, 2003